Pfizer Signs Commercial Agreement with Tabuk Pharmaceuticals

February 16, 2017 – Pfizer Saudi Limited signed an exclusive commercial agreement with Tabuk Pharmaceuticals. The deal will permit Pfizer to advertise and promote branded and high-value generic drugs, such as medicines that provide treatment for kidney dialysis, kidney transplant, urology, and the central nervous system. This agreement is part of a larger Vision 2030 effort to strengthen local manufacturing capabilities. Pfizer started production at a $50 million plant in Saudi Arabia in January.

Return to news page

©2015 U.S.-Saudi Arabian Business Council. All Rights Reserved. | Site Design By The Lone Designer
RSS Feed Twitter LinkedIn